GLPG1690
10mM in DMSO
- Product Code: 190287
CAS:
1628260-79-6
| Molecular Weight: | 588.70 g./mol | Molecular Formula: | C₃₀H₃₃FN₈O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD31544330 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
GLPG1690 is primarily investigated for its therapeutic potential in treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring of lung tissue. It functions as a selective inhibitor of autotaxin, an enzyme involved in the production of lysophosphatidic acid (LPA), a signaling molecule that contributes to fibrosis, inflammation, and cell proliferation. By reducing LPA levels, GLPG1690 aims to slow down or prevent the progression of fibrosis in the lungs.
Clinical trials have evaluated its efficacy and safety in patients with IPF, showing potential in improving lung function and reducing disease advancement. Due to its targeted mechanism, GLPG1690 represents a promising approach in managing fibrotic diseases beyond IPF, including other interstitial lung diseases and conditions involving pathological fibrosis. Its oral bioavailability also supports convenient long-term treatment regimens for chronic conditions.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿7,480.00 |
+
-
|
GLPG1690
GLPG1690 is primarily investigated for its therapeutic potential in treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring of lung tissue. It functions as a selective inhibitor of autotaxin, an enzyme involved in the production of lysophosphatidic acid (LPA), a signaling molecule that contributes to fibrosis, inflammation, and cell proliferation. By reducing LPA levels, GLPG1690 aims to slow down or prevent the progression of fibrosis in the lungs.
Clinical trials have evaluated its efficacy and safety in patients with IPF, showing potential in improving lung function and reducing disease advancement. Due to its targeted mechanism, GLPG1690 represents a promising approach in managing fibrotic diseases beyond IPF, including other interstitial lung diseases and conditions involving pathological fibrosis. Its oral bioavailability also supports convenient long-term treatment regimens for chronic conditions.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :